Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001628280-25-021830
Filing Date
2025-05-02
Accepted
2025-05-02 16:09:00
Documents
23
Period of Report
2025-04-24

Document Format Files

Seq Description Document Type Size
1 PRE 14A ovid-20250502.htm   iXBRL PRE 14A 712232
6 ovid-20250502_g1.jpg GRAPHIC 242993
7 ovid-20250502_g2.jpg GRAPHIC 77344
8 ovid-20250502_g3.jpg GRAPHIC 53509
9 ovid-20250502_g4.jpg GRAPHIC 45719
10 ovid-20250502_g5.jpg GRAPHIC 171906
11 ovid-20250502_g6.jpg GRAPHIC 130895
  Complete submission text file 0001628280-25-021830.txt   3144840

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20250502.xsd EX-101.SCH 3119
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ovid-20250502_def.xml EX-101.DEF 4323
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20250502_lab.xml EX-101.LAB 5033
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20250502_pre.xml EX-101.PRE 3369
25 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20250502_htm.xml XML 87086
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-38085 | Film No.: 25908512
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)